Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14704)	9/17/2000 9:08:54 PM
From: aknahow	Respond to of 17367

I have not mentioned the kids, nor any highminded ideals. My complaint is with the process of decision making within the FDA. I fully support the concept to seek approval only through "commercially practical" paths. The F.D.A. has dealt body breaking body blows to SCIOS, which had secured pannel recomendation for approval only to be turned down by the FDA. Managain had a new approach just as good as existing antibiotics. It was turned down because it was not beter. But wait are we not told how bad the situation is with regard to antibiotic resistance? Would not a new non-antibiotic approach be worth approving? The FDA was involved in the design of the trial. I wonder what they required XOMA to incorporate and what impact it had on the outcome. No there should be no further Meningococcemia trial. I feel XOMA should proceed to do whatever management feels best at this point.